Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma

Status:
Completed

Trial end date:
2013-01-01

Target enrollment:

Participant gender:

The purpose of this study is to test the safety of an investigational combination drug/immunotherapy for the treatment of Stage III/IV melanoma.

Phase 1

Ziopharm